Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 321

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 321
---
ida Ventures III-A, L.P. and Vida Ventures III, L.P. are collectively referred to as the “Vida Funds.” Vida Ventures GP                                              
 III, L.L.C., or Vida GP, is the general partner of each of the Vida Funds. Vida Ventures Management Co., LLC is the management company of the Vida Funds. Dr. Jain, a member of our board of directors, is a managing member of Vida GP. Each of 
 Vida GP and Dr. Jain may be deemed to have voting and dispositive power with respect to the shares owned by the Vida Funds. Each of Vida GP and Dr. Jain disclaims beneficial ownership of such shares, except to the extent of their            
 respective pecuniary interests therein. The address for each of these entities and individuals is 10100 Santa Monica Blvd, 15th Floor, Los Angeles, CA 90067.                                                                                    |

| (3) | Consists of (i) 261,120 shares of common stock issuable upon conversion of shares of our redeemable convertible                                                                                
 preferred stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 149,276 shares of common stock issuable upon conversion of shares of our redeemable convertible |

215

| preferred stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P.                                                       
 L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the        
 Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities. The address of each of the Pontifax Entities is c/o The Pontifax Group, 
 14 Shenkar Street, Herzelia, Israel.                                                                                                                                                                                                                    |

| (4) | Consists of 410,397 shares of common stock issuable upon conversion of shares of our redeemable convertible                                                                                                                                             
 preferred stock held by TCG Crossover Fund II, L.P. TCG Crossover GP II, LLC is the general partner of TCG Crossover Fund II,